Enlyte provides the most accurate view of continued trends in pharmacy management, by analyzing drug utilization and spending trends in workers’ comp on an annual basis. Our 2023 series reflects on the trends our clients experienced in 2022, providing an overall picture of both in- and out-of-network prescriptions in a four-part series coming throughout the year.
Part 1: Evaluating Retail and Mail Order Prescriptions
As employees head back into the office, we are seeing claim counts beginning to normalize with pharmacy trends following suit. In 2022 our retail and mail order channels continued to see positive results through pharmacy program management.
Top 3 Retail and Mail Order Trends
Join Tom Kerr as he interviews Nikki Wilson, Senior Director of Clinical Pharmacy Services to take a deeper dive into part one of our annual drug trends series. In this short video they will discuss standout trends from our most recent retail and mail order data focusing on three observations uncovered within the analysis regarding opioids, migraine medications, and topicals.
Part 2: Evaluating In- and Out-of-Network Trends
Out-of-network prescriptions represent an area of additional opportunity for clinical and cost controls and can often be associated with high-cost drugs. Leveraging both bill review and pharmacy data provides additional visibility into transactions from third-party billers, physician-dispensers, and co-mingled hospital and office visit bills. This analysis features the trends experienced within our combined in- and out-of-network channels to identify a total view of prescription activity.
Out-of-Network Dispensing Channels and Unique Challenges
Join Tom Kerr as he interviews Nikki Wilson, Senior Director of Clinical Pharmacy Services to dive deeper into part two of our annual drug trends series. In this short video they will discuss aggregate trends and challenges within our combined in- and out-of-network channels to address the total view of prescription activity.
Part 3: Evaluating Opioids
Opioids continue to represent a decreasing proportion of overall scripts and costs, with favorable trends seen in important markers such as morphine equivalent dose (MED), duration of use, and access to guideline-supported measures including medication-assisted treatment (MAT) and overdose rescue medication (naloxone).
Why Opioid Trends Are Changing in Workers’ Comp
In this Enlyte exclusive podcast, Nikki Wilson, Sr. Director, Clinical Pharmacy Services, takes a deeper dive into the continuing decline of opioid use and the strategies being used to manage them. Wilson focuses on medications driving the activity within the class, why opioids are still considered a high-impact drug class despite their decline, approaches to ensure appropriate opioid utilization moving forward, and how to manage opioid use disorder and minimize their risks. Listen here or click below to read the full conversation.
Part 4: High Impact Drug Classes
Categories such as topicals, compound kits, combo packs, and specialty medications represent proportionately low workers' comp utilization, however, they can be associated with exponentially significant costs. Recognizing the trends related to such cost drivers can help promote clinically appropriate savings.
Why High-Impact Drugs Are Taking a Bigger Piece of Pharm Spend
Part 4 of Enlyte’s Drug Trends Report uncovered significant cost increases in high-impact drug classes, despite relatively low utilization and effectiveness in comp injuries. This includes a topical prescription on the market which has the same active ingredients as OTC products such as a $10 tube of Bengay but with a price tag of $1,500. In this Enlyte-exclusive podcast, Nikki Wilson, Sr. Director, Clinical Pharmacy Services, details why this is happening and how it can be better managed.